<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682119</url>
  </required_header>
  <id_info>
    <org_study_id>17807</org_study_id>
    <secondary_id>2020-004290-46</secondary_id>
    <secondary_id>J2D-MC-CVAC</secondary_id>
    <nct_id>NCT04682119</nct_id>
  </id_info>
  <brief_title>A Safety Study of LY3526318 in Healthy Participants</brief_title>
  <official_title>A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about how the drug is absorbed in to the&#xD;
      blood stream and how it is eliminated from the body. The safety and tolerability of LY3526318&#xD;
      will also be evaluated when given by mouth either by single or multiple doses to healthy&#xD;
      participants. The study will have two parts. Each participant will enroll in only one part.&#xD;
      For each participant, Part A will last up to 44 days and Part B will last up to 50 days,&#xD;
      including screening and follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Actual">April 21, 2021</completion_date>
  <primary_completion_date type="Actual">April 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3526318</measure>
    <time_frame>Part A: Predose on Day 1 through Day 5; Part B: Predose on Day 1 through Day 8</time_frame>
    <description>PK: AUC of LY3526318</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of LY3526318</measure>
    <time_frame>Part A: Predose on Day 1 through Day 5; Part B: Predose on Day 1 through Day 8</time_frame>
    <description>PK: Cmax of LY3526318</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3526318 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3526318 administered orally as single ascending doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3526318 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3526318 administered orally as multiple doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3526318</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3526318 (Part A)</arm_group_label>
    <arm_group_label>LY3526318 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy males or females, as determined through medical history and&#xD;
             physical examination&#xD;
&#xD;
          -  Have a body mass index (BMI) between 18 and 32 kilograms per square meter (kg/mÂ²)&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history or presence of medical illness including, but not limited to,&#xD;
             cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or&#xD;
             neurological disease, convulsions, or any clinically significant laboratory&#xD;
             abnormality&#xD;
&#xD;
          -  Have an abnormality in the 12-lead electrocardiogram (ECG)&#xD;
&#xD;
          -  Have a history of clinically significant multiple or severe drug allergies&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV&#xD;
             antibodies, hepatitis C and/or positive hepatitis C antibody, or hepatitis B and/or&#xD;
             positive hepatitis B surface antigen.&#xD;
&#xD;
          -  Have an abnormal blood pressure&#xD;
&#xD;
          -  Have received treatment with biologic agents (such as monoclonal antibodies, including&#xD;
             marketed drugs) within 3 months or 5 half-lives (whichever is longer)&#xD;
&#xD;
          -  Are unwilling to stop herbal supplements, over the counter or prescription medicines&#xD;
&#xD;
          -  Are currently enrolled in a clinical drug study or any other type of medical research&#xD;
             judged not to be scientifically or medically compatible with this study.&#xD;
&#xD;
          -  Participants with a history of drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9728</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 1, 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

